Furiex Makes Inroads In Tough-To-Treat IBS-d With Phase III Eluxadoline Data
This article was originally published in Pharmaceutical Approvals Monthly
Eluxadoline met endpoints in two Phase III studies, positioning the drug for submission in a sparsely served therapeutic area, with only one FDA-approved drug and millions of patients in the U.S. and EU. Mild pancreatitis was reported in a handful of patients, but is manageable, company says.
You may also be interested in...
Biotech set to develop patented special-release statin formulation for a new approach to constipation-predominant irritable bowel syndrome – methane gas. The same research also underpins development of Salix’ Xifaxan for diarrhea-predominant IBS.
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.